SCHEMBL23975012

SCHEMBL23975012

COc1cccc(C(=O)NCC(=O)N[C@@H](C)c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 18/20 1.00
MEN1 O00255 1/20 0.71
KMT2A Q03164 1/20 0.71
ATM Q13315 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23975221 0.83 GPR139 (1.00) GPR139MEN1KMT2AATM
SCHEMBL30518967 0.83 GPR139 (1.00) GPR139MEN1KMT2AATM
SCHEMBL5672356 0.79 HPGD (0.72) GPR139MEN1KMT2A
SCHEMBL29742390 0.78 ROCK1 (0.71) GPR139
SCHEMBL28642442 0.78 ROCK1 (0.71) GPR139
SCHEMBL8947214 0.76 MAPK1 (0.72) GPR139MEN1KMT2A
SCHEMBL31178805 0.76 MAPK1 (0.72) GPR139MEN1KMT2A
SCHEMBL18794448 0.75 GPR139 (0.60) GPR139MEN1KMT2A
SCHEMBL9115329 0.75 GPR139 (0.74) GPR139MEN1KMT2A
SCHEMBL13754276 0.75 ALDH1A1 (0.77) GPR139MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12303511-B2 Methods related to opioid therapeutics UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-05-20 US disclosed
US-20240342180-A1 METHODS RELATED TO OPIOID THERAPEUTICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-10-17 US disclosed
US-12042496-B2 Methods related to opioid therapeutics THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-07-23 US disclosed
US-20210338680-A1 METHODS RELATED TO OPIOID THERAPEUTICS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240342180-A1 METHODS RELATED TO OPIOID THERAPEUTICS OPRL1, OPRK1, GPR139 GPR139 3/4885MEN1 4873/4885KMT2A 1691/4885
US-12042496-B2 Methods related to opioid therapeutics OPRL1, OPRK1, GPR139 GPR139 3/4885MEN1 4873/4885KMT2A 1691/4885
US-20210338680-A1 METHODS RELATED TO OPIOID THERAPEUTICS OPRL1, OPRK1, GPR139 GPR139 3/4885MEN1 4873/4885KMT2A 1691/4885
US-12303511-B2 Methods related to opioid therapeutics OPRL1, OPRK1, GPR139 GPR139 3/4885MEN1 4873/4885KMT2A 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.